Pre-made Casirivimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-096

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-096 Category Tag

Product Details

Pre-Made Casirivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial “antibody cocktail” designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. It consists of two monoclonal antibodies, casirivimab (REGN10933) and imdevimab (REGN10987) that must be mixed together. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product.

Products Name (INN Index)

Pre-Made Casirivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody

INN Name

Casirivimab

Target

SARS-CoV-2 Spike RBD

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

NFD

100% SI Structure

6xdg:BD

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2020

Companies

Regeneron Pharmaceuticals

Conditions Approved

COVID-19

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SARS-CoV-2Spike RBD

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide